102 related articles for article (PubMed ID: 22799326)
1. Association of two polymorphisms of DNA polymerase beta in exon-9 and exon-11 with ovarian carcinoma in India.
Khanra K; Panda K; Bhattacharya C; Mitra AK; Sarkar R; Bhattacharyya N
Asian Pac J Cancer Prev; 2012; 13(4):1321-4. PubMed ID: 22799326
[TBL] [Abstract][Full Text] [Related]
2. Exon 8-9 mutations of DNA polymerase β in ovarian carcinoma patients from Haldia, India.
Khanra K; Panda K; Mitra AK; Sarkar R; Bhattacharya C; Bhattacharya N
Asian Pac J Cancer Prev; 2012; 13(8):4183-6. PubMed ID: 23098424
[TBL] [Abstract][Full Text] [Related]
3. Association of a newly identified variant of DNA polymerase beta (polβΔ63-123, 208-304) with the risk factor of ovarian carcinoma in India.
Khanra K; Bhattacharya C; Bhattacharyya N
Asian Pac J Cancer Prev; 2012; 13(5):1999-2002. PubMed ID: 22901161
[TBL] [Abstract][Full Text] [Related]
4. Association between newly identified variant form of DNA polymerase beta (Δ 208-304) and ovarian cancer.
Khanra K; Panda K; Bhattacharya C; Mitra A; Sarkar R; Banerjee S; Bhattacharyya N
Cancer Biomark; 2012; 11(4):155-60. PubMed ID: 23144153
[TBL] [Abstract][Full Text] [Related]
5. Detection of Somatic Mutation in Exon 12 of DNA Polymerase β in Ovarian Cancer Tissue Samples.
Khanra K; Choudhuri I; Bhattacharyya N
Iran Biomed J; 2018 Sep; 22(5):355-9. PubMed ID: 29524322
[TBL] [Abstract][Full Text] [Related]
6. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
7. Splice variants but not mutations of DNA polymerase beta are common in bladder cancer.
Thompson TE; Rogan PK; Risinger JI; Taylor JA
Cancer Res; 2002 Jun; 62(11):3251-6. PubMed ID: 12036941
[TBL] [Abstract][Full Text] [Related]
8. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
Lee YJ; Lee MY; Ruan A; Chen CK; Liu HP; Wang CJ; Chao WR; Han CP
Oncotarget; 2016 Dec; 7(50):82097-82103. PubMed ID: 27888800
[TBL] [Abstract][Full Text] [Related]
9. HeLa Cells Containing a Truncated Form of DNA Polymerase Beta are More Sensitized to Alkylating Agents than to Agents Inducing Oxidative Stress.
Khanra K; Chakraborty A; Bhattacharyya N
Asian Pac J Cancer Prev; 2015; 16(18):8177-86. PubMed ID: 26745057
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the DNA polymerase beta gene in breast cancer.
Sliwinski T; Ziemba P; Morawiec Z; Kowalski M; Zadrozny M; Blasiak J
Breast Cancer Res Treat; 2007 Jun; 103(2):161-6. PubMed ID: 17131038
[TBL] [Abstract][Full Text] [Related]
11. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
14.
Na K; Kim EK; Jang W; Kim HS
Anticancer Res; 2017 Jun; 37(6):3249-3258. PubMed ID: 28551672
[TBL] [Abstract][Full Text] [Related]
15. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism of DNA polymerase beta hyper-expression in malignant transformation induced by benzo[a] pyrene].
Zhao W; Wu M; Yang M; Zhang ZZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):801-6. PubMed ID: 23387201
[TBL] [Abstract][Full Text] [Related]
17. TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?
Gupta M; Babic A; Beck AH; Terry K
Hum Pathol; 2016 Aug; 54():82-91. PubMed ID: 27068525
[TBL] [Abstract][Full Text] [Related]
18. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
19. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
20. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
